William C. Shakespeare of ARIAD Pharm to speak at 6th Protein Kinase Conference, May 27, 2011 Boston
William C. Shakespeare, Ph.D., Vice President, Drug Discovery at ARIAD Pharmaceuticals to give featured presentation on "Tackling Mutation-Based Resistance in Kinase Drug Discovery: Ponatinib, a Pan-BCR-ABL Inhibitor and AP26113, A Next Generation ALK Inhibitor" at GTCbio's 6th Protein Kinases in Drug Discovery Conference on May 26-27, 2011 in Boston, MA.
- Boston, MA-NH (1888PressRelease) February 25, 2011 - Dr. Shakespeare will address how mutation-based resistance is an inevitable consequence of targeted kinase inhibitor therapy. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor that potently inhibits all known resistant BCR-ABL mutations, including the T315I gatekeeper mutation. AP26113 is a next generation ALK inhibitor that overcomes mutations that confer resistance to crizotinib. A brief overview leading to the discovery of ponatinib will be described and the biological characterization of AP26113 will be reviewed.
Dr. Shakespeare has served as ARIAD's Vice President of Drug Discovery since April 2009 and has held multiple positions since joining ARIAD in July 1996. Prior to ARIAD, he was a Senior Research Scientist at Astra AB where he focused on CNS research.
Also presenting at the Protein Kinase Conference are prestigious organizations including Abbott, Ansaris, Arqule, Avila Tx, Biogen Idec, Boehringer Ingelheim, Dana Farber, DE Shaw Research, Genentech, Harvard Medical School, Invitrogen, Millennium, Merck, Novartis, OSI Pharma, Pfizer, and other leaders in the kinase industry. For more information, please visit http://www.gtcbio.com.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam